alpha-aminopyridine has been researched along with Genome Instability in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, BM; Claus, EB; Du, R; Goel, S; Guo, H; Hayashi, M; Iglehart, JD; Kang, YJ; Krop, IE; Ligon, AH; Ligon, KL; Lin, NU; Luu, V; Marco, E; Nguyen, QD; Ni, J; Ramkissoon, LA; Ramkissoon, SH; Roberts, TM; Stover, DG; Wang, ZC; Winer, EP; Xie, S; Yuan, GC; Zhao, JJ | 1 |
1 other study(ies) available for alpha-aminopyridine and Genome Instability
| Article | Year |
|---|---|
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Breast Neoplasms; Carrier Proteins; Caspase 3; Cell Cycle Proteins; DNA Repair; Drug Resistance, Neoplasm; Drug Therapy, Combination; Eukaryotic Initiation Factors; Everolimus; Female; Gene Expression Profiling; Genomic Instability; Humans; Immunohistochemistry; Ki-67 Antigen; Magnetic Resonance Imaging; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, SCID; Molecular Targeted Therapy; Morpholines; Multiprotein Complexes; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Receptor, ErbB-2; Remission Induction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |